eCOA

Medidata eCOA is an electronic clinical outcome assessment solution designed for sponsors and CROs who need to capture high-quality outcomes data from patients, clinicians, and caregivers without introducing rework, delays, or uncertainty into their studies. Built with real patient insight, the platform balances patient experience with scientific rigor, supporting everything from simple eDiaries to complex eClinROs across a wide range of therapeutic areas and study types.

The solution is purpose-built to accelerate study build timelines, improve patient engagement, and deliver real-time insights that enable faster, more confident decision-making throughout the life of a clinical trial. Medidata eCOA is recognized as a Leader in Everest Group's eCOA PEAK Matrix® Assessment 2025 and has demonstrated the ability to reduce study build timelines by up to 50%.

Core Capabilities

• Integrated Patient Experience: Patients interact with Medidata eCOA through a single, familiar interface that can also support consent, payments, and other study interactions, reducing fragmentation and keeping patients engaged over time for more complete outcome data.
• Site-Ready Workflows: The platform is designed to support site productivity with streamlined workflows that reduce administrative burden and help sites operate efficiently.
• Faster Study Build with AI: Medidata Designer enables study builders to configure questionnaires using intuitive drag-and-drop screen templates and visual workflow tools, delivering an average study start time of 8 weeks compared to the industry standard of 12 weeks.
• Comprehensive Real-Time Insights: Sponsors and CROs gain access to real-time eCOA data to support ongoing monitoring and decision-making throughout the study.
• Proven in Complex Studies: The solution is validated for use across a broad spectrum of studies, from simple vaccine trial eDiaries to complex eClinROs in CNS trials.

Study Build and Instrument Management

• Study build timelines average 8 weeks, up to 50% faster than the industry standard of 12 weeks, enabled by Medidata Designer's drag-and-drop configuration tools.
• A global instrument library allows teams to store and reuse standardized instrument builds and validated translations across multiple studies, supporting a "build once and deploy everywhere" approach.
• Pre-validated instruments can be rapidly deployed across studies, ensuring consistency and reducing duplicated effort for sponsors managing multiple trials.

Patient Engagement and Device Flexibility

• Medidata eCOA supports both provisioned devices and Bring Your Own Device (BYOD) models, compatible with iOS and Android platforms, accessible via web or mobile apps.
• Patients can complete assessments at home, on-site, or on the go, reducing patient burden and improving compliance rates.
• A unified patient experience consolidates eCOA alongside consent, payments, and other study interactions to minimize confusion and sustain long-term engagement.

Complex Therapeutic Area Support

• Through a partnership with Cogstate, Medidata eCOA provides a deeply integrated solution for CNS trials, streamlining workflows from rater training and data capture through to data quality oversight.
• The integration is specifically designed to enhance endpoint data quality in CNS studies, where assessment complexity is highest.
• The platform is suitable for a wide range of therapeutic areas and assessment types, from straightforward eDiaries to complex clinician-reported outcomes.

Training and Support

• Medidata offers a variety of training options for clients and partners, including both self-paced and instructor-led courses available through the Medidata Global Education and Training section.
• Professional services are available to support implementation and ongoing study operations.

Medidata eCOA is part of the broader Medidata Platform, which encompasses patient, data, and study experiences. The solution is designed to deliver measurable operational efficiency and platform savings, with metrics indicating significant cost savings and workdays saved per study for organizations running trials at scale.